Besivance is a suspension/ophthalmic drop medication owned by Bausch And Lomb. Containing the active ingredient besifloxacin hydrochloride, Besivance was initially authorized for market use on May 28, 2009. The product currently holds a total of four patents.
The generic version of Besivance is anticipated to be available after January 9, 2031. This follows the expiry of the last patent which is due on this date.
Besivance is primarily used for the treatment of ocular bacterial infections. The active ingredient, besifloxacin hydrochloride, significantly contributes to its effectiveness in managing these conditions.
Besivance, available as a generic after January 9, 2031, holds four patents. The last of these expires on January 9, 2031, and is titled 'Fluoroquinolone carboxylic acid molecular crystals.' Below are the details of the patent: